U.S. Markets open in 6 hrs 25 mins

Intercept Pharmaceuticals, Inc. (ICPT)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 4:00PM EDT
People also watch
PBYICLVSKITESRPTBLUE

Intercept Pharmaceuticals, Inc.

450 West 15th Street
Suite 505
New York, NY 10011
United States
646-747-1000
http://www.interceptpharma.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees456

Key Executives

NameTitlePayExercisedAge
Dr. Mark Pruzanski M.D.Founder, Chief Exec. Officer, Pres and Director1.04M7.64M49
Mr. Sandip S. KapadiaChief Financial Officer and Treasurer282.06kN/A47
Mr. David Shapiro M.D., Ph.D.Chief Medical Officer and Exec. VP of Devel.688.88k295.76k63
Dr. Rachel L. McMinn Ph.D.Chief Bus. and Strategy Officer592.51kN/A44
Ms. Lisa BrightPres of International614.81kN/A49
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. Its lead product candidate is obeticholic acid (OCA), a bile acid analog, which has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). The company is developing OCA to treat various non-viral progressive liver diseases, such as nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. It also provides OCA under the Ocaliva brand name for the treatment of primary biliary cholangitis in the United States and Europe. In addition, the company is developing INT-767, an orally administered dual FXR and TGR5 agonist for the treatment of liver fibrosis; and INT-777, an orally administered TGR5 agonist for the treatment of type 2 diabetes, associated metabolic disorders, and other gastrointestinal indications. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.

Corporate Governance

Intercept Pharmaceuticals, Inc.’s ISS Governance QualityScore as of May 1, 2017 is 6. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 5; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.